A DECADE OF PROGRESS IN STATISTICAL METHODOLOGY FOR CLINICAL-TRIALS

被引:25
作者
SIMON, R
机构
[1] National Cancer Institute Building EPN, Bethesda, Maryland, 20892
关键词
D O I
10.1002/sim.4780101203
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials played a dominant and expanding role in the evaluation of new treatments during the decade of the 1980s. There were major improvements in the quality of clinical trials in many medical fields. There were also important developments in the methodology of designing, monitoring, conducting, analysing, reporting and interpreting clinical trials. This paper attempts to review some of these developments. A comprehensive review is beyond the abilities of any one individual. Consequently, this paper attempts to offer a broad stroke description of this area and to highlight specific topics of importance based on my particular experience. An extensive, but non-comprehensive bibliography is included to provide entry points to the literature of methodologic developments for clinical trials in the 1980s.
引用
收藏
页码:1789 / 1817
页数:29
相关论文
共 229 条
[1]  
Armitage P., Sequential Medical Trials, (1960)
[2]  
Armitage P., Stratton I.M., Worthington H.V., Repeated significance tests for clinical trials with a fixed number of patients and variable follow‐up, Biometrics, 41, pp. 353-359, (1985)
[3]  
DeMets D.L., Practical aspects in data monitoring: A brief review, Statistics in Medicine, 6, pp. 743-760, (1987)
[4]  
DeMets D., Gail M., Use of logrank tests and group sequential methods at fixed calendar times, Biometrics, 41, pp. 1039-1044, (1985)
[5]  
DeMets D., Lan G., An overview of sequential methods and their application in clinical trials, Communications in Statistics A, 13, pp. 2315-2338, (1984)
[6]  
DeMets D., Stopping guidelines vs. stopping rules: A practitioner's point of view, Communications in Statistics A, 13, pp. 2395-2417, (1984)
[7]  
Enas G.G., Dornseif B.E., Sampson C.B., Rockhold F.W., Wuu J., Monitoring versus interim analysis of clinical trials: A perspective from the pharmaceutical industry, Controlled Clinical Trials, 10, pp. 57-70, (1989)
[8]  
Fairbanks K., Madsen R., P values for tests using a repeated significance test design, Biometrika, 69, pp. 69-74, (1982)
[9]  
Fleming T., Green S.J., Harrington D., Considerations for monitoring and evaluating treatment effects in clinical trials, Controlled Clinical Trials, 5, pp. 55-66, (1984)
[10]  
Fleming T., Harrington D., O'Brien P.O., Designs for group sequential tests, Controlled Clinical Trials, 5, pp. 348-361, (1984)